Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag datopotamab-deruxtecan

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

FDA

FDA Chemotherapy

PharmaShots Weekly Snapshots (January 30 - February 03, 2023)

PharmaShots

FEBRUARY 3, 2023

4D Molecular Therapeutics Receives the US FDA’s IND Clearance of 4D-150 for the Treatment of Diabetic Macular Edema Date: Feb 03, 2023 | Tags: 4D Molecular Therapeutics, 4D-150, Diabetic Macular Edema, Regulatory, US, FDA, IND AstraZeneca and Amgen Receive the US FDA’s Approval of Tezspire (tezepelumab) for the Treatment of Severe Asthma (..)

FDA

FDA Labelling

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

PharmaShots Weekly Snapshots (January 30 - February 03, 2023)

Stay Connected